Production (Stage)
COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.50M | 3.32M | 2.34M | 2.34M | 2.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.50M | 3.32M | 2.34M | 2.34M | 2.06M |
| Cost of Revenue | 1.06M | 1.27M | 1.52M | 1.52M | 1.15M |
| Gross Profit | 443.00K | 2.05M | 819.00K | 819.00K | 904.00K |
| SG&A Expenses | 2.93M | 2.75M | 3.04M | 3.04M | 1.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.12M | 6.93M | 6.09M | 6.09M | 3.87M |
| Operating Income | -3.62M | -3.61M | -3.76M | -3.76M | -1.81M |
| Income Before Tax | -3.66M | -5.65M | -1.90M | -1.90M | -1.81M |
| Income Tax Expenses | -- | 1.08M | -474.00K | -474.00K | -412.00K |
| Earnings from Continuing Operations | -3.66M | -6.73M | -1.42M | -1.42M | -1.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.66M | -6.73M | -1.42M | -1.42M | -1.40M |
| EBIT | -3.62M | -3.61M | -3.76M | -3.76M | -1.81M |
| EBITDA | -3.29M | -3.56M | -3.38M | -3.38M | -1.46M |
| EPS Basic | -1.16 | -2.14 | -0.64 | -0.64 | -0.76 |
| Normalized Basic EPS | -0.73 | -0.57 | -0.53 | -0.53 | -0.61 |
| EPS Diluted | -1.16 | -2.14 | -0.64 | -0.64 | -0.76 |
| Normalized Diluted EPS | -0.73 | -0.57 | -0.53 | -0.53 | -0.61 |
| Average Basic Shares Outstanding | 3.14M | 3.14M | 2.22M | 2.22M | 1.85M |
| Average Diluted Shares Outstanding | 3.14M | 3.14M | 2.22M | 2.22M | 1.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |